Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is a chemotherapy regimen used with palliative intent in these patients. Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the retrospective study of PEP-C use in relapsed/refractory lymphoma patients over an 8-year period. The data will allow for physicians to use this utilize this regimen and improve patients quality of life during the end-of-life phase. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
PEP-C for lymphoma palliative care: a regional experience in the UK
